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Summary
Objectives: In our hospital, a continuous intervention program aimed at optimizing the quality of
antibiotic use was introduced by late 1999 and antibiotic consumption was a major outcome for
assessment. However, healthcare conditions have been subject to change over the last five years,
and a pronounced economic crisis in 2002 affected the availability of antibiotics. Therefore, we
hypothesized that the consumption of these drugs could be a suitable indirect marker of the crisis.
Design: We performed segmented regression analysis between different periods. Variations in
antibiotic consumption during periods corresponding to the four-phase intervention program
(from 1999 to the first six months of 2001) were assumed to be ‘intervention-induced’, while
those observed during the crisis period were considered as ‘situation-enforced’.
Results: Whereas the intervention-induced (desirable) decrease of total antibiotic and carba-
penem consumption proved to correlate with a decreased crude mortality rate during the control
period prior to the crisis (R2, 0.82 and 0.91, respectively), the crisis-induced (undesirable)
decrease in total antibiotic and carbapenem consumption correlated with an increased mortality
during this phase (R2, 0.80 and 0.75, respectively).
Conclusions: Our results illustrate that a reduction in antibiotic consumption does not always
represent a favorable outcome from an intervention program on prescribing practice. Moreover,
it may be a sensitive indirect marker of a deficient healthcare condition leading to an increase in
in-hospital mortality.
# 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.* Corresponding author. Tel.: +54 343 4310783;
fax: +54 343 4310783.
E-mail address: cbantar@arnet.com.ar (C. Bantar).
1201-9712/$32.00 # 2006 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2005.05.012Introduction
Inappropriate use of antibiotics is a widely recognized pro-
blem. Thus, consumption of these drugs is considered aPublished by Elsevier Ltd. All rights reserved.
232 C. Bantar et al.crucial target to be assessed as a main outcome from inter-
ventions on antimicrobial prescribing practices.1,2 However,
developing countries may go through periods with deficient
healthcare conditions that affect the availability of antimi-
crobial agents.3 In these conditions, reduction of antibiotic
consumption may not represent a favorable outcome. In our
hospital, a continuous intervention program aimed at opti-
mizing the quality of antibiotic use was introduced by late
1999 and antibiotic consumption was a major outcome for
assessment.4 However, healthcare conditions have been sub-
ject to change over the last five years, and a pronounced
economic crisis in 2002 affected the availability of antibio-
tics. Therefore, we hypothesized that the consumption of
these drugs could be a suitable indirect marker of the crisis
and performed segmented regression analysis to elucidate
this issue.
Design and methods
Hospital San Martı´n is a 250-bed public teaching hospital for
adult patients. It is located in Parana´, Argentina, a city of
about 350 000 inhabitants. By 1999, within the context of
alarmingly high rates of nosocomial infection and increasing
antibiotic consumption, a Service of Infection Control was
created.5 This multidisciplinary team was then convened to
design a four-phase (sixmonths each) sequential intervention
program to optimize antibiotic use within the hospital.4
Briefly, at the baseline period during the last six months of
1999, an optional antibiotic order form was introduced.
Later, during the first six months of 2000, use of this form
was made obligatory for the procurement of antibiotics from
the pharmacy. The antibiotic order form required the phy-
sician to state the hospitalization ward, the demographic
data for the patient, the certainty of infection diagnosis
(e.g., possible, definitive or laboratory-documented), the
origin (community- or hospital-acquired) and source of infec-
tion, the antibiotic dosage and the estimated length of
therapy. The pharmacist did not deliver any antibiotic with-
out the fulfillment of the obligatory order form within the
intervention period (a pharmacist was on duty 24 hours per
day, seven days per week). These two phases were followed
by the addition of policing activity for every antibiotic order
(except for surgical prophylaxis, which was already standar-
dized). During these subsequent two periods (last six months
of 2000 and first six months of 2001), the infectious diseases
physician (IDP) and the clinical microbiologist checked the
order forms within the first 24—48 h after prescription and
discussed every therapy with the attending physician. At the
late phase (i.e., the last step of the program, first six months
of 2001), the multidisciplinary team, if necessary, could
modify prescriptions after internal discussion in accordance
with its clinical and therapeutic experience, following the
criteria of evidence-based medicine. The IDP completed a
unique form with the same data as the antimicrobial order
form, with additional data such as the grade of severity of
disease. Both the attending physician prescription and the
final treatment adopted after discussion with the team
members were stated on the form. Data were finally
recorded and analyzed by using the Epi Info statistical pack-
age (version 6.0, Center for Disease Control and Prevention,
Atlanta, GA, USA). This latter strategy was then adopted tocontrol antibiotic use within our hospital, and has been
continued up to the present day.
There were no restrictions on the initial antibiotic pre-
scribing intention in any period. However, significant supply
shortages followed in the wake of the financial crisis that
affected our country by the end of 2001, and continued
during the whole of 2002. Consequently, several antibiotics
became scarcely obtainable and sometimes not available at
all. Furthermore, during this crisis, the hospital went through
several strike periods and staff reductions. Consequently,
surgery, radiology, and blood products services were kept to a
minimum and some ceased working completely. This crisis
was gradually overcome throughout 2003. Therefore, for
analysis purposes, we defined periods as follows: (i) pre-
intervention (before the creation of the Infection Control
Service), from 1997 to the first six month of 1999; (ii) baseline
(before the introduction of the antimicrobial program), the
last six months of 1999; (iii) initial intervention, the whole of
2000; (iv) active control, the last six months of the four-phase
intervention program (first six months of 2001); (v) pre-crisis
control, last six months of 2001; (vi) crisis control, the whole
of 2002; (vii) post-crisis control, the whole of 2003; and (viii)
out-of-crisis control, the first six months of 2004.
Consumption of antibiotics was recorded as total grams of
the drug on a homemade computerized system (SOUFARMA)6
and then converted into defined daily dose (DDD) per 1000
patient-days in accordance with World Health Organization
recommendations.7 Only the expenditure on drugs adminis-
tered intravenously was analyzed. Antibiotic consumption
associated with surgical prophylaxis was excluded. Variations
in antibiotic consumption during periods corresponding to
the four-phase intervention program (from 1999 to the first
six months of 2001) were assumed to be ‘intervention-
induced,’ while those observed during the crisis period were
considered as ‘situation-enforced’.
Density of nosocomial infection was estimated as pre-
viously described5 in every period. Bacterial resistance rates
were recorded and analyzed by a previously described home-
made computerized system (SIR) developed by one of the
authors (CB).8 Data concerning number of patient-days and
crude mortality (i.e., inpatient all-cause mortality) were
kindly supplied by the Department of Statistics. All rates
were expressed as number of events per 1000 patient-days.
Segmented regression analysis was used to assess the sig-
nificance of changes in level, mean consumption, and slope of
the regression lines between the four-phase intervention
period (1999 to early 2001, four time points) and the control
during the crisis period (late 2001 to early 2003, four time
points). Trends over time and correlation among variables
were assessed by simple linear regression analysis performed
on the software Statistix for Windows, ver. 2.0 (Analytical
Software Co.). The difference in mean antibiotic consumption
between periods was assessed by the rank sum two-sample
(Mann—Whitney) test. Other rates and proportions were ana-
lyzed by comparison with the Chi-square or the Fisher’s exact
tests. A p value of 0.05 was regarded as significant.
Results
In order to get a rough picture of patient mix, we assessed
some characteristics of the infections for which antibiotics
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Table 1 Characteristics of infections for which antibiotics were ordered during an intervention on antimicrobial prescribing
practice throughout changing conditions in healthcare
Characteristic
of infection
Frequency (%) at the following periods a
Baseline
(450)
Active control
(349)
Pre-crisis control
(348)
Crisis control
(535)
Post-crisis
control (396)
Out-of-crisis
control (418)
Site
Abdomen 8.0 12.5 18.1 15.1 14.6 9.6
Bone 6.2 1.8 4.6 5.2 3.0 5.7
CNS 0.9 2.4 2.6 1.5 2.5 1.4
Catheter 1.8 11.9 b 4.3 4.5 3.0 3.1
Lung 28.2 b 50.6 45.7 42.6 46.5 45.7
Skin and soft tissue 4.8 7.7 9.5 11.8 12.6 15.3
Urinary tract 6.1 8.3 7.8 9.5 13.1 8.4
Others 0.3 3.0 7.1 1.0 1.7 5.5
Unknown 43.7 b 4.9 4.5 8.8 c 3.0 5.3
Origin
Community 39.8 d 45.8 c 45.5 c 66.4 64.9 69.8
Hospital 60.2 54.2 55.5 33.6 35.1 31.2
Severity
Low 5.2 4.8 5.2 3.5 4.3 6.6
Moderate 56.9 54.8 56.9 53.6 51.3 53.4
High 37.9 40.4 37.9 42.9 44.4 40.0
CNS: central nervous system.
a See definitions of periods in the text for detail. Values in parentheses indicate the total number of prescriptions assessed in every period.
b p < 0.0001 versus all the control periods.
c p < 0.05 versus the remaining control periods.
d p < 0.0001 versus crisis, post- and out-of-crisis control.
Figure 1 Interrupted time series analyses to assess the differ-
ences between induced (intervention) and enforced (crisis)
changes in antibiotic consumption. See definitions of periods
in the text for detail.were ordered within the different periods. Data are pre-
sented in Table 1. Prescriptions ordered for cases of unknown
source of infection decreased significantly after interven-
tion, increased during the crisis and returned to the pre-crisis
period values during the post-crisis and out-of-crisis control
phases. Prescriptions directed to nosocomial-acquired infec-
tions were more frequent during the baseline, pre-crisis and
crisis phases, as compared with the subsequent control
periods. Prescriptions for catheter-related infections were
more frequent during the active control period. Otherwise,
differences between periods were unremarkable.
Variations in nosocomial infection rates and consumption
of several intravenous antibiotics observed throughout the
different periods are shown in Table 2. Although we observed
the lowest rate of global nosocomial infection during the
crisis, the specific incidence of both Gram-negative rods
resistant to broad-spectrum cephalosporins and methicil-
lin-resistant Staphylococcus aureus increased significantly
during this phase. Paradoxically, consumption of carbape-
nems (either imipenem or meropenem), cefepime, ciproflox-
acin and vancomycin proved to be dramatically reduced
during the same period.
The interrupted time series analysis was attempted by
segmented regression to assess the changes in total intrave-
nous antibiotic consumption occurring from the fourth-phase
intervention period (‘intervention-induced’ variation) to the
crisis control period (‘situation-enforced’ variation). The
outcome features are shown in Figure 1. A sudden decrease
in the total antibiotic level was observed from the initial
intervention—active control phase to the crisis control per-iod, with significant differences in mean consumption
between periods. Furthermore, the decreasing slope of total
antibiotic consumption was less pronounced during the crisis
period.
The longitudinal assessment of total antibiotic and carba-
penem consumption, as well as the crude mortality, are
plotted in Figure 2. From 1997 to 1999 (pre-intervention
to baseline) a sustained increase was observed in both car-
bapenem consumption and crude mortality rate (R2 = 0.98,
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Table 2 Variations in nosocomial infection rates and consumption of several intravenous antibiotics during an intervention on
antimicrobial prescribing practice throughout changing conditions in healthcare
Feature a Rate at the following period b
Baseline Active
control
Pre-crisis
control
Crisis
control
Post-crisis
control
Out-of-crisis
control
Nosocomial infection (No. per 1000 patient-days)
Global 8.0 8.9 9.1 4.2 6.5 4.7
BSCep-R-Gram () 3.1 1.7 0.6 c 2.7 c 1.4 1.2
MRSA 2.1 0.7 0.8 1.4 c 0.7 0.7
Antibiotic consumption (DDD per 1000 patient-days)
Ciprofloxacin 16.0 17.5 18.1 12.1 c 18.9 18.4
Carbapenems 13.5 6.2 4.7 1.3 c 1.8 c 4.1
Oxyimino-cephalosporins 92.3 42.3 31.8 32.8 19.2 33.1
Cefepime 3.9 8.8 4.4 0.1 c 0.5 c 3.8
Piperacillin/tazobactam 0 0 0 0 15.3 0
Aminopenicillin/sulbactam 24.7 22.9 27.7 24.4 22.1 21.6
Vancomycin 28.5 20.7 19.6 10.7 c 12.0 c 20.2
a BSCep-R-Gram (): Gram-negative rods resistant to broad-spectrum cephalosporins; MRSA: methicillin-resistant Staphylococcus aureus;
DDD: defined daily doses; oxyimino-cephalosporins include ceftazidime and ceftriaxone; carbapenems include imipenem and meropenem.
b See definitions of periods in the text for detail.
c Statistically significant differences ( p < 0.05) versus the remaining control periods.p = 0.0001 and R2 = 0.82, p = 0.01, respectively). A simple
linear regression analysis showed a modest, but statistically
significant, relationship between the respective increases of
these two variables (R2 = 0.71, p = 0.03). By contrast, neither
sustained trend nor correlation with crude mortality could be
demonstrated for the total intravenous antibiotic consump-
tion. From the last six months of 1999 (baseline) to the first
six months of 2001 (intervention prior to the crisis), a
decrease in the consumption (i.e., ‘intervention-induced’
variation) of both total antibiotics and carbapenem occurred
in parallel to a decrease in the crude mortality rate. A simple
linear regression analysis showed a close relationship
between decrease in mortality and decrease in carbapenem
consumption (R2 = 0.91, p = 0.04), as well as a statistically
non-significant trend with decrease in the total antibiotic
consumption (R2 = 0.82, p = 0.06). By contrast, from lateFigure 2 Variation of (*) total intravenous antibiotic con-
sumption (Y1-axis, DDD per 1000 patient-days), (~) carbapenem
(imipenem andmeropenem) consumption (Y2-axis, DDD per 1000
patient-days) and (&) crude mortality (Y2-axis, No. per 1000
patient-days) throughout changing healthcare conditions. See
definitions of periods in the text for detail.2001 (pre-crisis) to early 2003 (post-crisis), a decrease in
both carbapenem and total antibiotic consumption (i.e.,
‘situation-enforced’ variation) proved to correlate with an
increase in mortality rate (R2 = 0.75, p = 0.04 and R2 = 0.80,
p = 0.05, respectively).
Discussion
The vast majority of the studies on control of antibiotic use
take into account cost savings or antibiotic consumption1,9,10
as the variables to ascertain the success of interventions,
but, with only a few exceptions,1,4 the duration of follow-up
throughout intervention periods has mostly been short (less
than two years). Therefore, the performance of such inter-
ventions through periods of changing healthcare conditions
has scarcely been assessed.
Because carbapenems were the most expensive antibiotic
used in our hospital, we hypothesized that they might be a
sensitive indirect marker of the crisis. At this point, two
different situations should be distinguished. On the one hand,
the sustained increase in carbapenem consumption, corre-
lating with an increasing crude mortality during the pre-
intervention period, probably reflects the overuse and mis-
use of these drugs. This is in the setting of a healthcare
system in a chaotic condition, where antibiotics were still
largely available, but with high nosocomial infection rates
within a hospital lacking an Infection Control Service and
policy on antibiotic use, such as we already described.5,6
Unfortunately, we are not able to definitively elucidate this
hypothesis, as data on nosocomial infections were not avail-
able before the creation of our Service. However, the fact
that after intervention, during four periods with stable con-
ditions (i.e., late 1999 to early 2001), the intervention-
induced decrease of carbapenem consumption correlated
with a decreasing crude mortality rate, seems to support
this notion. On the other hand, during the crisis, the carba-
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ity. Moreover, during this period, the pronounced reduction
of carbapenem consumption occurred despite the significant
increase in Gram-negative rods resistant to broad-spectrum
cephalosporins, but carbapenem-susceptible (Table 2). This
fact suggests that this drug was underused during this period.
Therefore, our results show that reduction in carbapenem
use during the crisis is far from representing a favorable
outcome. It should be emphasized that although these find-
ings do not necessarily indicate that decrease in carbapenem
consumption was the cause for the mortality increase, its
assessment was useful to reflect indirectly the impact of our
transitory healthcare crisis, when other relevant resources
also ceased to be available (e.g., blood components, inter-
ventional radiology, surgery facilities, etc.).
Consumption of intravenous antimicrobials has previously
been regarded as a suitable outcome to assess the quality of
intervention on prescribing practice.1,11 Ansari et al.11
applied segmented regression to interrupted time series
analysis for describing the changes in consumption of certain
intravenous ‘alert antibiotics’ observed between before- and
after-intervention periods, and found this method to be a
suitable tool. The British Society for Antimicrobial Che-
motherapy, together with the Hospital Infection Society,
has also used this method to evaluate the current evidence
based on the effectiveness of interventions to change anti-
biotic prescribing and emphasized the advantages of this
model.12 However, both of the above studies took into
account solely the variation of antibiotic consumption as
the effectiveness outcome of intervention. Despite the low
number of time series points used in our segmented regres-
sion model, the interrupted time serial assessment applied to
a ‘before- and after-crisis’ setting was able to describe
properly the significant enforced reduction in the consump-
tion of antibiotics that occurred during the crisis. A subse-
quent linear regression analysis evidenced the correlation of
the decrease of intervention-induced and crisis-enforced
antibiotic consumption with reducing and increasing mortal-
ity rates, respectively. As shown for carbapenems, vancomy-
cin consumption was drastically reduced during the crisis, as
was ciprofloxacin and cefepime, even in the setting of
increasing rates of infections caused by methicillin-resistant
Staphylococcus aureus. In summary, the present study
demonstrates that reduction of intravenous antibiotic con-
sumptionmay not always represent a desirable outcome from
an intervention program. Moreover, it may be a sensitive
indirect marker of a deficient healthcare condition leading to
an increase in in-hospital mortality, not necessarily attribu-
table to infectious causes. Performing segmented regression
analysis seems to be a powerful tool for use in cases of
changing healthcare resource availability.
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